Abstract
GARP is a transmembrane protein present on stimulated human regulatory T lymphocytes (Tregs), but not on other T lymphocytes (Th cells). It presents the latent form of TGF-β1 on the Treg surface. We report here that GARP favors the cleavage of the pro-TGF-β1 precursor and increases the amount of secreted latent TGF-β1. Stimulated Tregs, which naturally express GARP, and Th cells transfected with GARP secrete a previously unknown form of latent TGF-β1 that is disulfide-linked to GARP. These GARP/TGF-β1 complexes are possibly shed from the T cell surface. Secretion of GARP/TGF-β1 complexes was not observed with transfected 293 cells and may thus be restricted to the T cell lineage. We conclude that in stimulated human Tregs, GARP not only displays latent TGF-β1 at the cell surface, but also increases its secretion by forming soluble disulfide-linked complexes. Moreover, we identified six microRNAs (miRNAs) that are expressed at lower levels in Treg than in Th clones and that target a short region of the GARP 3' UTR. In transfected Th cells, the presence of this region decreased GARP levels, cleavage of pro-TGF-β1, and secretion of latent TGF-β1.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Blotting, Western
-
Enzyme-Linked Immunosorbent Assay
-
HEK293 Cells
-
Humans
-
Immunoprecipitation
-
Luciferases
-
Membrane Proteins / immunology*
-
Membrane Proteins / metabolism
-
MicroRNAs / metabolism*
-
Reverse Transcriptase Polymerase Chain Reaction
-
T-Lymphocytes, Regulatory / immunology*
-
T-Lymphocytes, Regulatory / metabolism
-
Transforming Growth Factor beta1 / metabolism*
Substances
-
LRRC32 protein, human
-
Membrane Proteins
-
MicroRNAs
-
Transforming Growth Factor beta1
-
Luciferases
Grants and funding
E.G., J.S., G.B., J.-F.C. and S.L. are supported by the Fonds National pour la Recherche Scientifique (Belgium). J.C. is supported by a post-doctoral fellowship from the Fonds Spéciaux de la Recherche (Belgium) and C.H. is supported by a Télévie grant (Belgium). This work was supported by grants from the Belgian Programme on Interuniversity Poles of Attraction initiated by the Belgian State, Prime Minister's Office, Science Policy Programming, by grants from the Belgian Cancer Plan (Action 29_049), the Fonds National pour la Recherche Scientifique (Belgium), the Fondation contre le Cancer (Belgium), the Fondation Salus Sanguinis (Belgium), the Actions de Recherche Concertées (Belgium) and the Fonds J. Maisin (Belgium). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.